Animal Health Biotechnology in the US: Market Size, Businesses & Forecast 2026

The animal health biotechnology industry in the United States comprises firms utilizing advanced biological processes, genetic engineering, and molecular diagnostics to develop veterinary therapeutics, vaccines, and production-enhancing treatments for livestock and companion animals. The industry's direction is increasingly shaped by precision medicine, monoclonal antibody therapies, and gene-editing applications intended to secure food supplies and treat chronic diseases in pets. For instance, Zoetis Inc., a prominent market operator, reported a total global revenue of 9.5 billion USD in 2025 (Zoetis Inc. Annual Report 2025), reflecting a stable but highly competitive operating environment

Industry snapshot

Key public data points

Historical & forecast

Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.

What does the Animal Health Biotechnology in the US industry cover?

The industry encompasses the research, development, and manufacturing of veterinary biological products, molecular diagnostic kits, and recombinant technologies for animals. It serves two distinct categories: livestock/commercial production animals and companion animals. The biological scope covers advanced veterinary vaccines, nucleic-acid-based therapeutics, gene-edited reproductive tools, and cellular therapies.

• •Focuses on veterinary biologics regulated under the Virus-Serum-Toxin Act.
• •Includes advanced diagnostic platforms like PCR and ELISA for zoonotic disease monitoring.
• •Excludes conventional chemically synthesized veterinary pharmaceuticals.

Who operates in the industry and how is it structured?

The market features a highly consolidated core of large multinational animal health companies alongside a fragmented ecosystem of specialized biotechnology startups and academic spin-offs. Large operators utilize strategic partnerships, licensing agreements, and outright acquisitions to absorb early-stage biotech innovations. Production is strictly tied to specialized manufacturing facilities that comply with federal biosafety and quality controls.

• •Dominated by a small number of global players with dedicated U.S. research infrastructures.
• •Relies on contract research organizations (CROs) for conducting veterinary clinical trials.
• •Operations are concentrated in agricultural research hubs and biotech clusters across states like Kansas, Iowa, and California.

What drives demand in the industry?

Market demand is primarily propelled by the ongoing necessity to combat emerging zoonotic and infectious animal diseases, which threaten global food security and public health. In the companion animal sector, rising pet ownership and an increased consumer willingness to pay for premium, human-grade veterinary medical treatments drive the adoption of monoclonal antibodies and long-term therapeutic regimens. Additionally, commercial livestock producers demand biometric and genetic optimization tools to maximize yield efficiencies.

• •Outbreaks of highly pathogenic avian influenza and swine fevers necessitate rapid vaccine development.
• •Increased consumer spending on senior pet care for chronic conditions like osteoarthritis and cancer.
• •Federal programs addressing antimicrobial resistance (AMR) push livestock operators toward biological alternatives over traditional antibiotics.

Who are the notable companies in the industry?

Competition within the U.S. landscape is intense, centering on product innovation pipelines, intellectual property portfolios, and regulatory speed-to-market. Major public and multinational corporate participants maintain diversified product lines spanning parasiticide biologics, livestock vaccines, and diagnostic equipment. Companies continuously update their pipelines through lifecycle innovations and geographic expansions.

• •Zoetis Inc. operates as a leading independent public company in this sector, achieving 9.5 billion USD in global revenue for 2025.
• •Elanco Animal Health Incorporated competes heavily across both companion animal and livestock biological segments.
• •Merck & Co., Inc. conducts extensive U.S. veterinary biotechnology operations through its subsidiary Merck Animal Health.
• •Boehringer Ingelheim International GmbH operates a significant U.S. presence from its animal health division, focused heavily on swine and equine biologics.

What are the recent trends and outlook?

Recent developments are characterized by an acceleration in the approval of species-specific monoclonal antibodies designed to manage chronic pain and atopic dermatitis. The industry is also pivoting toward digital and biotechnology integration, where diagnostic datasets inform preventative biological treatments. The outlook for 2026 indicates moderate domestic operational headwinds due to shifting channel inventories, balanced by strong international demand for livestock biologics.

• •Approval and commercial scaling of advanced monoclonal therapies such as those targeting canine and feline osteoarthritis.
• •Growing utilization of genomic profiling and biomarker assays in commercial dairy and beef cattle management.
• •Zoetis Inc. issued a full-year 2026 revenue guidance of 9.825 billion to 10.025 billion USD, signaling an expected organic operational growth of 3% to 5%.

How is the industry regulated?

The regulatory framework for animal biotechnology in the United States is complex and divided among multiple federal agencies under the Coordinated Framework for the Regulation of Biotechnology. Regulatory oversight is determined by the product's primary mode of action, composition, and intended use. Compliance requires rigorous validation of safety, purity, potency, and environmental impact before any commercial release.

• •The USDA Animal and Plant Health Inspection Service (APHIS) regulates veterinary biologics, including vaccines and diagnostics, under the Virus-Serum-Toxin Act.
• •The Food and Drug Administration (FDA) Center for Veterinary Medicine (CVM) regulates animal drugs, food additives, and intentionally altered genomic DNA in animals.
• •The Environmental Protection Agency (EPA) oversees topical treatments and biotechnological pest-control products under the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA).

Government, statistical and trade sources used for this Claight analysis.

• Zoetis Inc. Annual Report 2025 ·
• Zoetis Inc. Q4 and Full Year 2025 Financial Results ·
• USDA Animal and Plant Health Inspection Service (APHIS) ·
• FDA Center for Veterinary Medicine (CVM)